<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">0213264</journal-id>
<journal-id journal-id-type="pubmed-jr-id">1117</journal-id>
<journal-id journal-id-type="nlm-ta">Biol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Biol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Biological psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0006-3223</issn>
<issn pub-type="epub">1873-2402</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30826071</article-id>
<article-id pub-id-type="pmc">6482952</article-id>
<article-id pub-id-type="doi">10.1016/j.biopsych.2019.01.008</article-id>
<article-id pub-id-type="manuscript">NIHMS1522841</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Electrophysiological phenotype in Angelman syndrome differs between genotypes</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Frohlich</surname>
<given-names>Joel</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Miller</surname>
<given-names>Meghan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bird</surname>
<given-names>Lynne M.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Garces</surname>
<given-names>Pilar</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Purtell</surname>
<given-names>Hannah</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hoener</surname>
<given-names>Marius C.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Philpot</surname>
<given-names>Benjamin D.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sidorov</surname>
<given-names>Michael S.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tan</surname>
<given-names>Wen-Hann</given-names>
</name>
<xref ref-type="aff" rid="A6">6</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hernandez</surname>
<given-names>Maria-Clemencia</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Rotenberg</surname>
<given-names>Alexander</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jeste</surname>
<given-names>Shafali S.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Krishnan</surname>
<given-names>Michelle</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Khwaja</surname>
<given-names>Omar</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hipp</surname>
<given-names>Joerg F.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, Switzerland</aff>
<aff id="A2"><label>2</label>Center for Autism Research and Treatment University of California, Los Angeles Semel Institute for Neuroscience, USA</aff>
<aff id="A3"><label>3</label>Department of Pediatrics, University of California, San Diego; Genetics / Dysmorphology, Rady Children's Hospital San Diego, California, USA</aff>
<aff id="A4"><label>4</label>Department of Neurology, Boston Children's Hospital; Harvard Medical School, Boston, Massachusetts, USA</aff>
<aff id="A5"><label>5</label>Neuroscience Center, Carolina Institute for Developmental Disabilities, and Department of Cell Biology &amp; Physiology, University of North Carolina, Chapel Hill, NC, USA</aff>
<aff id="A6"><label>6</label>Division of Genetics and Genomics, Boston Children’s Hospital; Harvard Medical School, Boston, Massachusetts, USA</aff>
<author-notes>
<corresp id="CR1"><label>*</label>Correspondence to: <email>joelfrohlich@gmail.com</email>, <email>joerg.hipp@roche.com</email></corresp>
<fn id="FN1">
<p id="P1"><bold>Joerg F. Hipp</bold>, Roche Pharma Research and Early Development, Neuroscience, Ophthalmology and Rare Diseases, Roche Innovation Center Basel, Grenzacherstrasse 124, CH-4070 Basel, Switzerland; <email>joerg.hipp@roche.com</email>; Phone: +41-6168-22382</p>
</fn>
<fn fn-type="COI-statement" id="FN4">
<p id="P42">Disclosures</p>
<p id="P43">Pilar Garces, Maria-Clemencia Hernandez, Joerg F. Hipp, Marius Hoener, Omar Khwaja, Michelle Krishnan and Meghan Miller are full-time employees of F. Hoffmann-La Roche Ltd.; Joel Frohlich is a former employee of F. Hoffmann-La Roche Ltd. (until July 2017); Shafali Jeste, Benjamin Philpot, and Alexander Rotenberg serve as a consultants for and have received funding from F. Hoffmann-La Roche Ltd.. All other authors report no biomedical financial interests or potential conflicts of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>6</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>19</day>
<month>1</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="ppub">
<day>01</day>
<month>5</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2020</year>
</pub-date>
<volume>85</volume>
<issue>9</issue>
<fpage>752</fpage>
<lpage>759</lpage>
<!--elocation-id from pubmed: 10.1016/j.biopsych.2019.01.008-->
<abstract id="ABS1">
<sec id="S1">
<title>Background:</title>
<p id="P2">Angelman syndrome is a severe neurodevelopmental disorder caused by either disruptions of the gene <italic>UBE3A</italic> or deletion of chromosome 15 at 15q11-q13, which encompasses <italic>UBE3A</italic> and several other genes, including <italic>GABRB3</italic>, <italic>GABRA5</italic>, <italic>GABRG3</italic> encoding GABA type-A receptor (GABA<sub>A</sub>R) subunits (β3, α5, γ3). Individuals with deletions are generally more impaired than those with other genotypes, but the underlying pathophysiology remains largely unknown. Here we used electroencephalography (EEG) to test the hypothesis that genes other than <italic>UBE3A</italic> located on 15q11-q13 cause differences in pathophysiology between AS genotypes.</p>
</sec>
<sec id="S2">
<title>Methods:</title>
<p id="P3">We compared spectral power of clinical EEG recordings from children (age: 1 – 18 years) with a deletion genotype (<italic>n</italic> = 37), a non-deletion genotype (<italic>n</italic> = 21), and typically developing children without Angelman syndrome (<italic>n</italic> = 48).</p>
</sec>
<sec id="S3">
<title>Results:</title>
<p id="P4">We found elevated theta power (peak frequency: 5.3 Hz) and diminished beta power (peak frequency: 23 Hz) in the deletion genotype compared to the non-deletion genotype, as well as excess broadband EEG power (1-32 Hz) peaking in the delta frequency range (peak frequency: 2.8 Hz) shared by both genotypes but stronger for the deletion genotype at younger ages.</p>
</sec>
<sec id="S4">
<title>Conclusions:</title>
<p id="P5">Our results provide strong evidence for the contribution of non-UBE3A neuronal pathophysiology in deletion AS and suggest that hemizygosity of the <italic>GABRB3-GABRA5-GABRG3</italic> gene cluster causes abnormal theta and beta EEG oscillations that may underlie the more severe clinical phenotype. Our work improves the understanding of AS pathophysiology and has direct implications for the development of AS treatments and biomarkers.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Angelman syndrome</kwd>
<kwd>EEG</kwd>
<kwd>GABA</kwd>
<kwd>UBE3A</kwd>
<kwd>biomarkers</kwd>
<kwd>GABRB3-GABRA5-GABRG3 gene cluster</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>